Reduction in Lipoprotein (a) With the PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A Pooled Analysis of Over 1300 Patients in 4 Phase 2 Trials

Study Questions:

What is the effect of PCSK9 inhibition on circulating levels of lipoprotein (a) [Lp(a)]?